Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Gross Margin (2016 - 2025)

Adma Biologics' Gross Margin history spans 13 years, with the latest figure at 63.82% for Q4 2025.

  • For Q4 2025, Gross Margin rose 994.0% year-over-year to 63.82%; the TTM value through Dec 2025 reached 57.39%, up 590.0%, while the annual FY2025 figure was 57.39%, 590.0% up from the prior year.
  • Gross Margin reached 63.82% in Q4 2025 per ADMA's latest filing, up from 56.34% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 63.82% in Q4 2025 to a low of 10.73% in Q1 2021.
  • Average Gross Margin over 5 years is 31.07%, with a median of 28.69% recorded in 2022.
  • Peak YoY movement for Gross Margin: tumbled -10582bps in 2021, then surged 2737bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 6.38% in 2021, then surged by 344bps to 28.36% in 2022, then skyrocketed by 48bps to 42.06% in 2023, then rose by 28bps to 53.88% in 2024, then grew by 18bps to 63.82% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Gross Margin are 63.82% (Q4 2025), 56.34% (Q3 2025), and 55.11% (Q2 2025).